Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
INSERM maintains a patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio has 1 pending office action. This activity involves 1 distinct examiner and a distinct art unit, indicating a specific area of active prosecution. This concentrated profile is often seen in research-heavy organizations that focus on high-value biological or pharmaceutical discoveries.
STAVROU, CONSTANTINA E is the busiest examiner for INSERM, with the busiest examiner pending office action. Within the Biotechnology & Pharmaceuticals sector, this single pending action is the primary focus of the company's current patent office interactions. The resolution of this action will determine the immediate progress of the portfolio's active filings. Practitioners should note that because all active prosecution is channeled through a single examiner, the specific nuances of this examiner's review style will heavily influence the organization's patenting success. This single-point prosecution strategy requires careful management of the pending office action to ensure the desired intellectual property protections are secured.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STAVROU, CONSTANTINA E | 1 | 42.4% | +35.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996901 | ANIMAL MODEL FOR STUDYING CANCER IMMUNOTHERAPY | STAVROU, CONSTANTINA E | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17996901 | ANIMAL MODEL FOR STUDYING CANCER IMMUNOTHERAPY | STAVROU, CONSTANTINA E | 1632 | §103 | Final Rejection | — | Pending | Oct 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialINSERM has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Constantina E Stavrou has the most, with 1 of INSERM's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
